

Clinical Trial Budget Estimate: ImmunoFolate for ARDS (Phase 2)

Trial Size: 100 patients

Design: Double-blind, placebo-controlled

Duration: 12 months (6–9 months enrollment + 3 months follow-up/reporting)

Sites: 3–5 hospitals with ICU enrollment capacity

Category	Estimated Cost (USD)	Notes
1. Site Costs		
Site start-up fees (IRB, contracting)	\$75,000	\$15K/site × 5 sites
Per-patient payments	\$750,000	\$7,500/patient average (screening, treatment, follow-up)
Site monitoring (CRA)	\$120,000	~\$2,000/monitoring visit × 60 visits
Subtotal Site Costs	\$945,000	

| 2. Clinical Supplies |||

| ImmunoFolate production (GMP) | \$150,000 | Includes formulation, QC, packaging (pilot GMP run) |

| Placebo production | \$50,000 | Matched formulation and blinding |

| Labeling, storage, distribution | \$25,000 | Central pharmacy and shipping to sites |

| **Subtotal Clinical Supplies** | **\$225,000** ||

| 3. Central Services |||

| Central lab tests (cytokines, CRP, safety labs) | \$120,000 | \$1,200/patient × 100 |

| Imaging (CXR/CT if protocol-mandated) | \$60,000 | If required; can be standard-of-care |

| Electronic data capture (EDC) system | \$45,000 | Includes setup, licenses, hosting |

| Randomization/IWRS system | \$25,000 | Interactive web response system for blinding |

| Data management and biostatistics | \$85,000 | Database cleaning, analysis, reporting |

| Medical writing and CSR | \$30,000 | Clinical Study Report preparation |

| **Subtotal Central Services** | **\$365,000** ||

| 4. Regulatory & Oversight |||

| IND preparation and maintenance | \$40,000 | Includes pre-IND briefing, annual updates |

| Independent DSMB | \$30,000 | Quarterly safety review meetings |

| QA/QC audits | \$15,000 | 1–2 audits total |

| IRB central fees | \$15,000 | Optional centralized IRB |

| **Subtotal Regulatory** | **\$100,000** ||

| 5. Project Management and Overhead |||

| Project manager (0.5–1.0 FTE) | \$120,000 | 12 months @ ~\$10K/mo |

| Sponsor oversight (internal team or CRO) | \$60,000 | Travel, meetings, oversight |

Insurance (clinical trial liability)	\$25,000	Industry average premium
Contingency (10%)	\$180,000	Buffer for unexpected costs
Subtotal Management & Overhead	**\$385,000**	

 **Total Estimated Budget: \$2,020,000**

Optional Add-Ons (if needed):

- **Pharmacokinetic study sub-cohort:** +\$100,000
- **Biobanking of patient samples:** +\$50,000
- **Patient travel reimbursement:** +\$20,000
- **Expanded number of sites (e.g., 10):** +\$300,000